Niclosamide-13C6

Niclosamide-13C6 is the 13C6 labeled Niclosamide. Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.

Product Specifications

CAS Number

[1325808-64-7]

Product Name Alternative

BAY2353-13C6

UNSPSC

12352005

Hazard Statement

H315, H318

Target

Antibiotic; Isotope-Labeled Compounds; Parasite; STAT

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; JAK/STAT Signaling; Others; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/niclosamide-13c6.html

Purity

99.0

Solubility

10 mM in DMSO|H2O : 0.1mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N[13C]1=[13CH][13CH]=[13C]([N+]([O-])=O)[13CH]=[13C]1Cl)C2=CC(Cl)=CC=C2O

Molecular Formula

C7 13C6H8Cl2N2O4

Molecular Weight

333.08

Precautions

H315, H318

References & Citations

[1]Chen, M., et al., The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry, 2009. 48 (43) : p. 10267-74.|[2]Jin, Y., et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res, 2010. 70 (6) : p. 2516-27.|[3]Ren, X., et al., Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Medicinal Chemistry Letters, 2010. 1 (9) : p. 454-459.|[4]Wu CJ, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48 (7) :2693-6.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.